<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The T cell response to B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> differs from the majority of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> in that the malignant cells themselves are derived from B lymphocytes, key players in immune response </plain></SENT>
<SENT sid="1" pm="."><plain>B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are therefore well situated to manipulate their surrounding microenvironment to enhance <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and minimize anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> T cell responses </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed the effect of T cells on the growth of a transplantable B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and found that iNKT cells suppressed the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> CD8(+) T cell response </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002665'>Lymphoma</z:hpo> cells transplanted into syngeneic <z:mp ids='MP_0002169'>wild type</z:mp> (WT) mice or Jalpha18(-/-) mice that specifically lack iNKT cells grew initially at the same rate, but only the mice lacking iNKT cells were able to reject the <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>This effect was due to the enhanced activity of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific CD8(+) T cells in the absence of iNKT cells, and could be partially reversed by reconstitution of iNKT cells in Jalpha 18(-/-) mice </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-bearing WT mice with alpha -galactosyl <z:chebi fb="7" ids="17761">ceramide</z:chebi>, an activating ligand for iNKT cells, reduced the number of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific CD8(+) T cells </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, <z:hpo ids='HP_0002665'>lymphoma</z:hpo> growth in CD1d1(-/-) mice that lack both iNKT and type II NKT cells was similar to that in WT mice, suggesting that type II NKT cells are required for full activation of the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immune response </plain></SENT>
<SENT sid="7" pm="."><plain>This study reveals a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-promoting role for iNKT cells and suggests their capacity to inhibit the CD8(+) T cell response to B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by opposing the effects of type II NKT cells </plain></SENT>
</text></document>